Company profile
Orgenesis Inc.
OTC: ORGS · Healthcare · Biotechnology
#867 of 1,418 Healthcare companies by revenuetop-quartile growth
EA Score
——FH —DQ 60GM —SS 51
v0.1 · 25/100 weight · pillars only
↑ revenue growth (YoY), disclosure history · ↓ return on assets, balance-sheet leverage
Methodology →Revenue TTM
-$12.9M
Rev growth YoY (TTM)
-192.0%
Net income (FY)
-$48.2M
Employees
77
as of 2026-08-26
Market cap
$980.0k
as of 2026-08-26
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$1.0M$1.0M2024
Net income-$48.2M-$48.2M2024
Operating income-$39.8M-$39.8M2024
Total assets$1.4M$1.4M2024
Liabilities$38.9M$38.9M2024
Equity-$37.5M-$37.5M2024
Revenue trend
FY2018 – FY2024 · USD
FY18
FY19
FY20
FY20
FY21
FY22
FY23
FY24
Revenue by segment
Filed disclosures · FY2023
By product
Eliminations0%
By geography
Not disclosed.
The read
What is Orgenesis Inc.’s revenue?
Orgenesis Inc. booked $1.0M in FY2024 revenue, growing 95% year over year — faster than most Healthcare companies we track, at a -4653.6% net margin.
Peers · Healthcare
Matinas BioPharma Holdings, Inc.32DReflect Scientific, Inc.——First Choice Healthcare Solutions, Inc.27DMarijuana Company of America, Inc.——Dare Bioscience, Inc.36DSintx Technologies, Inc.35DNeighbors
Montgomery →Key facts
CEOVered Caplan
SectorHealthcare
IndustryBiotechnology
HeadquartersGermantown, MD
ExchangeOTC: ORGS
Employees77
IPO date2012-03-13
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.